A senior federal health official informed drug manufacturer Boehringer Ingelheim (BI) today its restrictions on 340B pricing when hospitals use contract pharmacies are illegal and must end immediately, or BI could face civil monetary penalties.
U.S. Health Resources and Services
…
The U.S. Health Resources & Services Administration (HRSA) today referred six drug manufacturers to the U.S. Health and Human Services Department of the Office of the Inspector General (HHS OIG) regarding their refusal to offer 340B discounts to 340B covered
…
The 340B drug pricing program has a new, higher profile home within the U.S. Health Resources and Services Administration (HRSA), and likely is getting a new director due to its current director’s promotion.
U.S. Health and Human Services (HHS) Secretary
…
Drug manufacturer Merck has begun informing 340B covered entities that, effective Sept. 1, it will stop providing 340B pricing to hospitals that partner with 340B contract pharmacies unless the hospitals share 340B claims data with its vendor 340B ESP.
Hospitals
…
The Biden administration said today it proposes to continue a nearly 30% reduction in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs.
The Trump administration implemented the payment reduction in January 2018. Hospital groups say it costs affected 340B hospitals
…
The U.S. Supreme Court this morning agreed to review a federal appeals court’s July 2020 ruling upholding a nearly 30% reduction in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.
The court’s decision to hear American Hospital Association (AHA)
…
Drug manufacturer Boehringer Ingelheim (BI) announced yesterday that it will stop shipping 340B-purchased drugs to hospitals’ contract pharmacies, effective Aug. 1.
Community health centers, HIV/AIDS clinics, and other federal grantee covered entities are exempt from BI’s new policy. It applies
…
A federal district judge in Delaware yesterday rejected the U.S. Health and Human Services Department’s (HHS) position that its withdrawal of its December 2020 advisory opinion on 340B contract pharmacy rendered drug manufacturer AstraZeneca’s claims against the opinion moot.
In
…
HHS Withdraws 340B Contract Pharmacy Advisory Opinion, Says May 17 Demand Letters Are Unaffected
The U.S. Health and Human Services Department (HHS) yesterday withdrew its December 2020 legal advisory opinion (AO) that the 340B statute unambiguously requires drug manufacturers to
…
Novartis Pharmaceuticals has sued the U.S. Health Resources and Services Administration (HRSA) over the agency’s May 17 letter telling the company its restrictions on 340B pricing to covered entities that use contract pharmacies are illegal.
Novartis told 340B Report late
…*Sign up for news summaries and alerts from 340B Report